Combined effects of eptifibatide and anticoagulants: Differences between LMWH and UH or rH in thrombin generation inhibition but not in platelet aggregation inhibition

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 1012-1019

  Koestenberger, Martin ^a   Gallistl, Siegfried ^a   Cvirn, Gerhard ^a   Roschitz, Birgit ^a   Petritsch, Martina ^a   Leschnik, Bettina ^a   Muntean, Wolfgang ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

Eptifibatide; LMWH; Platelet aggregation; Simultaneous determination; Thrombin generation

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; EPTIFIBATIDE; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; THROMBIN;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; MODEL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROVOCATION TEST; STATISTICAL SIGNIFICANCE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOCYTOPOIESIS; THROMBOGENESIS;

EID: 0036907719     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613348     Document Type: Article

References (37)

1. Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138: 1093-104.
2. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997; 80: 11B-20B.
3. Hemker HC, Beguin S. Thrombin generation in plasma: Its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-38.
4. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
5. Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RW, Kakkar V, Hemker HC, Beguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
6. Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1987; 1: 937-42.
7. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 2: 989-94.
8. Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 1994; 72: 387-92.
9. Gallistl S, Muntean W, Leis HJ. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma. Thromb Haemost 1995; 74: 1163-8.
10. Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-52.
11. Koestenberger M, Gallistl S, Cvirn G, Roschitz B, Muntean W. Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro. Blood Coagul Fibrinolysis 2000; 11: 425-32.
12. The IMPACT-II investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997; 349: 1422-8.
13. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Sriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KN, Califf RM, Krucoff MW, Topol EJ. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrillin in acute myocardial infarction. Circulation 1997; 95: 846-54.
14. The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
15. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.
16. Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM. Effect of SR 121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
17. Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
18. Butenas S, Cawthern KM, Van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
19. Li Y, Spencer FA, Ball S, Becker RC. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes. J Thromb Thrombolysis 2000; 10: 69-76.
20. Kleiman NS, Tracy RP, Talley JD, Sigmon K, Joseph D, Topol EJ, Califf RM, Kitt M, Ohman EM. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2000; 9: 5-12.
21. Suzuki YS, Hillyer P, Miyamoto S, Niewiaroski S, Sun L, Rao AK, Hollenbach S, Edmunds LH. Integrilin prevents prolonged bleeding times after cardiopulmonary bypass. Ann Thorac Surg 1998; 66: 373-81.
22. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Michelson AD, GPIIb-IIIa antagonist-induced in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84: 492-8.
23. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badibon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
24. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 252-50, 310-18.
25. Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
26. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
27. Van't Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II. J Biol Chem 1997; 272: 4367-77.
28. Rapaport SI. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
29. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-78.
30. Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagul Fibrinolysis 1996; 7: 459-64.
31. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 1699-712.
32. Cohen M, Theroux P, Weber S, Lavamee P, Huynh T, Borzak S, Diodati JG, Squiree IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273-81.
33. Hirsh J, Levineee MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
34. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralisation by platelet factor 4. Biochem J 1984; 218: 725-32.
35. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1989; 60: 457-62.
36. Weitz JI. Activation of blood coagulation by plaque rupture: Mechanisms and prevention. Am J Cardiol 1995; 75: 18B-22B.
37. Turpie AG. Clinical potential of antithrombotic drugs in coronary syndromes. Am J Cardiol 1998; 82: 11L-14L.